Arsenic reverses glioblastoma resistance to mTOR-targeted therapies

被引：7
|
作者：
Iwanami, Akio [1 ]
Cloughesy, Timothy F. [2 ]
Cavenee, Webster K. [3 ]
Mischel, Paul S. [3 ]
机构：
[1] Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo, Japan
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[3] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA
来源：
CELL CYCLE | 2013年 / 12卷 / 10期
关键词：
LEUKEMIA;
D O I：
10.4161/cc.24747
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：1473 / 1474
页数：2
相关论文
共 50 条
  • [1] Glutaminase-mediated metabolic pathway involves glioblastoma resistance to mTOR-targeted therapies
    Tanaka, Kazuhiro
    Sasayama, Takashi
    Irino, Yasuhiro
    Takata, Kumi
    Nagashima, Hiroaki
    Masui, Kenta
    Gini, Beatrice
    Yang, Huijun
    Mischel, Paul S.
    Kohmura, Eiji
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S73 - S73
  • [2] GLUTAMINASE-MEDIATED METABOLIC PATHWAY INVOLVES GLIOBLASTOMA RESISTANCE TO mTOR-TARGETED THERAPIES
    Tanaka, Kazuhiro
    Sasayama, Takashi
    Irino, Yasuhiro
    Takata, Kumi
    Nagashima, Hiroaki
    Masui, Kenta
    Gini, Beatrice
    Yang, Huijun
    Mischel, Paul S.
    Kohmura, Eiji
    NEURO-ONCOLOGY, 2014, 16
  • [3] Recent Clinical Trials of mTOR-Targeted Cancer Therapies
    Don, Aruni S. Arachchige
    Zheng, X. F. Steven
    REVIEWS ON RECENT CLINICAL TRIALS, 2011, 6 (01) : 24 - 35
  • [4] Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas
    Pierard-Franchimont, Claudine
    Hermanns-Le, Trinh
    Paquet, Philippe
    Herfs, Michael
    Delvenne, Philippe
    Pierard, Gerald E.
    FUTURE ONCOLOGY, 2015, 11 (22) : 2997 - 3002
  • [5] Unveiling Novel Avenues in mTOR-Targeted Therapeutics: Advancements in Glioblastoma Treatment
    Singh, Shilpi
    Barik, Debashis
    Lawrie, Karl
    Mohapatra, Iteeshree
    Prasad, Sujata
    Naqvi, Afsar R.
    Singh, Amar
    Singh, Gatikrushna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [6] Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies
    J Zhou
    J Luo
    K Wu
    E-j Yun
    P Kapur
    R-C Pong
    Y Du
    B Wang
    C Authement
    E Hernandez
    J Yang
    G Xiao
    T-L Cha
    H-C Wu
    D Wu
    V Margulis
    Y Lotan
    J Brugarolas
    D He
    J-T Hsieh
    Oncogene, 2016, 35 : 4663 - 4674
  • [7] Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies
    Zhou, J.
    Luo, J.
    Wu, K.
    Yun, E-j
    Kapur, P.
    Pong, R-C
    Du, Y.
    Wang, B.
    Authement, C.
    Hernandez, E.
    Yang, J.
    Xiao, G.
    Cha, T-L
    Wu, H-C
    Wu, D.
    Margulis, V.
    Lotan, Y.
    Brugarolas, J.
    He, D.
    Hsieh, J-T
    ONCOGENE, 2016, 35 (35) : 4663 - 4674
  • [8] PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
    Iwanami, Akio
    Gini, Beatrice
    Zanca, Ciro
    Matsutani, Tomoo
    Assuncao, Alvaro
    Nael, Ali
    Dang, Julie
    Yang, Huijun
    Zhu, Shaojun
    Kohyama, Jun
    Kitabayashi, Issay
    Cavenee, Webster K.
    Cloughesy, Timothy F.
    Furnari, Frank B.
    Nakamura, Masaya
    Toyama, Yoshiaki
    Okano, Hideyuki
    Mischel, Paul S.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (11) : 4339 - 4344
  • [9] Achieving cancer cell death with PI3K/mTOR-targeted therapies
    Yea, Sung Su
    Fruman, David A.
    INOSITOL PHOSPHOLIPID SIGNALING IN PHYSIOLOGY AND DISEASE, 2013, 1280 : 15 - 18
  • [10] Enhancing mTOR-targeted cancer therapy
    Wang, Xuerong
    Sun, Shi-Yong
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (10) : 1193 - 1203
12345